• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why SELLAS (SLS) Posted a Wider Net Loss but a Narrower Per-Share Loss This Quarter

    Simply Wall St·08/14/2026 07:23:48
    Listen to the news
    • SELLAS Life Sciences Group, Inc. reported past second-quarter 2026 results, with net loss rising to US$9.61 million from US$6.60 million a year earlier, while basic loss per share from continuing operations narrowed to US$0.05 from US$0.07.
    • Despite higher cumulative net losses in the first half of 2026, the company’s investment case is increasingly shaped by late-stage oncology programs such as galinpepimut-S and SLS009, supported by collaborations with Merck, GenFleet Therapeutics, and Memorial Sloan Kettering Cancer Center.
    • We’ll now examine how SELLAS’s progress with SLS009 for acute myeloid leukemia could influence the company’s broader investment narrative.

    Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

    What Is SELLAS Life Sciences Group's Investment Narrative?

    For SELLAS, the investment “big picture” is still all about whether its late‑stage oncology assets can justify today’s rich valuation, despite persistent losses and ongoing dilution. The latest Q2 2026 results, with net loss widening to US$9.61 million but loss per share improving, do not materially change the near‑term story: investors are primarily watching the Phase 3 REGAL trial for GPS and, increasingly, SLS009’s randomized Phase 2 program in acute myeloid leukemia, where topline data are expected in Q4 2026. The earnings update simply reinforces that SELLAS remains a pre‑revenue biotech reliant on the market and its US$150 million at‑the‑market facility to fund trials. That keeps financing risk, share dilution and trial execution at the center of the thesis, even as recent share price gains suggest optimism around these programs.

    However, the pace and scale of future equity raises is a risk investors should not ignore. The valuation report we've compiled suggests that SELLAS Life Sciences Group's current price could be inflated.

    Exploring Other Perspectives

    SLS 1-Year Stock Price Chart
    SLS 1-Year Stock Price Chart
    Investors in the Simply Wall St Community currently provide 1 fair value estimate at US$32.50, showing limited dispersion. Against this, SELLAS’s widening losses and dependence on future trial milestones may lead others to very different conclusions about the stock’s resilience and upside potential.

    Explore another fair value estimate on SELLAS Life Sciences Group - why the stock might be worth just $32.50!

    Form Your Own Verdict

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Seeking Other Investments?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.